Table 1.
Baseline characteristics of patients in the SCarlet RoAD study
| Variable | Intention-to-treat population (n = 797) | ||
|---|---|---|---|
| Placebo (n = 266) |
Gantenerumab 105 mg (n = 271) |
Gantenerumab 225 mg (n = 260) |
|
| Age, years, mean (SD) | 69.5 (7.5) | 70.3 (7.0) | 71.3 (7.1) |
| Education, years, mean (SD) | 89.8% | 93.0% | 91.9% |
| Weight, kg, mean (SD) | 12.6 (4.3) | 12.9 (4.8) | 12.1 (4.5) |
| APOE ε4 genotype, %a | 69.8 (12.9) | 70.5 (13.6) | 70.1 (12.5) |
| 0ε4 | 29.7% | 21.0% | 38.5% |
| 1ε4 | 50.4% | 41.0% | 61.5% |
| 2ε4 | 19.9% | 38.0% | – |
| Clinical scores | |||
| CDR-SB, mean score (SD) | 2.1 (1.0) | 2.2 (1.0) | 2.0 (0.9) |
| ADAS-Cog 13, mean score (SD) | 23.5 (7.2) | 23.1 (6.9) | 23.0 (6.2) |
| FAQ, mean score (SD) | 4.9 (4.3) | 4.6 (3.9) | 4.8 (4.3) |
| FCSRT-Total Recall, mean score (SD) | 29.3 (10.8) | 28.3 (10.8) | 30.5 (10.4) |
| MMSE, mean score (SD) | 25.7 (2.1) | 25.7 (2.3) | 25.7 (2.2) |
| CSF biomarkers | |||
| Aβ42, pg/ml, mean (SD) | 487.8 (170.4) | 475.3 (142.2) | 511.8 (172.0) |
| t-tau, pg/ml, mean (SD) | 556.3 (203.8) | 563.2 (239.1) | 544.5 (220.5) |
| p-tau, pg/ml, mean (SD) | 84.0 (31.4) | 86.3 (39.5) | 82.5 (34.2) |
| Neurogranin, pg/ml, mean (SD) | 474.8 (260.7) | 500.5 (270.0) | 484.9 (293.9) |
Abbreviations: ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, APOE Apolipoprotein E, CDR-SB Clinical Dementia Rating Sum of Boxes, CSF Cerebrospinal fluid, FAQ Functional Activities Questionnaire, FCSRT Free and Cued Selective Reminding Test, MMSE Mini Mental State Examination
aBy design, there were no APOE 2ε4 patients in the gantenerumab 225 mg arm